PE-Labeled Monoclonal Anti-Human CD19 Antibody, Mouse IgG2a (FMC63)
抗體來(lái)源（Source）
Monoclonal Anti-Human CD19 Antibody, Mouse IgG2a (FMC63) is a mouse monoclonal antibody recombinantly expressed from human 293 cells (HEK293), which provides higher batch consistency and long term security of supply.
應(yīng)用（Application）
Flow Cytometry (Detection the expression of CD19 on Human cells).
克隆號(hào)（Clone）
FMC63
種屬（Species）
Mouse
亞型（Isotype）
Mouse IgG2a | kappa
特異性（Specificity）
This product is a specific antibody specifically reacts with CD19 protein.
種屬反應(yīng)性（Reactivity）
Human
免疫原（Immunogen）
Human prolymphocytic leukaemia cell line JVM3.
偶聯(lián)（Conjugate）
PE
Excitation Wavelength: 488 nm / 561 nm
Emission Wavelength: 575 nm
同型對(duì)照（Isotype Control）
The Isotype control is sold separately and you can search for Cat. No. DNP-PM487 for product information.
推薦稀釋比（Recommended Dilution）
1:50
制劑（Formulation）
Lyophilized from 0.22 μm filtered solution in PBS, 0.03% Proclin 300, pH7.4, 0.2% BSA with trehalose as protectant.
Contact us for customized product form or formulation.
重構(gòu)方法（Reconstitution）
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存儲(chǔ)（Storage）
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please protect from light and avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 24 months in lyophilized state;
-70°C for 12 months after reconstitution.
2-8 °C for 12 months after reconstitution.
背景（Background）
FMC63 is an IgG2a mouse monoclonal antibody specific for CD19, which is a target for the immunotherapy of B lineage leukaemias and lymphomas. FMC63 scFv is the most commonly used ectodomain component of CD19-specific CARs. So far, most of reported CART19 trials contain the anti-CD19 scFv derived from FMC63, including the two FDA-approved CARs Kymriah and Yescarta.
關(guān)鍵字： CD19抗體;FMC63;FMC63抗體;ACRO;百普賽斯;
百普賽斯集團(tuán)ACROBiosystems Group（股票代碼：301080）是成立于2010年的跨國(guó)生物科技公司，是為全球生物醫(yī)藥、健康產(chǎn)業(yè)領(lǐng)域提供關(guān)鍵生物試劑產(chǎn)品及解決方案的行業(yè)平臺(tái)型基石企業(yè)。2021年在創(chuàng)業(yè)板上市。百普賽斯集團(tuán)業(yè)務(wù)遍布全球，橫跨亞洲、北美洲、歐洲，在中國(guó)、美國(guó)、瑞士等12個(gè)城市設(shè)有辦公室、研發(fā)中心及生產(chǎn)基地。目前累計(jì)服務(wù)客戶超6000家，與全球Top 20醫(yī)藥企業(yè)均建立了長(zhǎng)期、穩(wěn)定的合作伙伴關(guān)系。集團(tuán)旗下?lián)碛衅放艫CROBiosystems百普賽斯、bioSeedin柏思薈、Condense Capital墾拓資本和ACRODiagnostics百斯醫(yī)學(xué)等。